Black Diamond Therapeutics(US:BDTX)2025-12-03 13:20Financial Performance - Black Diamond Therapeutics reported a net loss of $8.5 million for Q3 2025, an improvement from a net loss of $15.6 million in Q3 2024[5]. - Total operating expenses for Q3 2025 were $10.98 million, compared to $18.13 million in Q3 2024[13]. - The accumulated deficit as of September 30, 2025, was $449.6 million, reduced from $487.1 million at the end of 2024[11]. - License revenue for the nine months ended September 30, 2025, was $70 million, with no license revenue reported for the same period in 2024[13]. Research and Development - Research and development expenses decreased to $7.4 million in Q3 2025 from $12.9 million in Q3 2024, primarily due to workforce efficiencies and outlicensing of BDTX-4933[5]. - Black Diamond plans to disclose objective response rate (ORR) and preliminary duration of treatment data from the Phase 2 trial of silevertinib later this quarter[4]. - Black Diamond is exploring partnership opportunities in NSCLC and glioblastoma to advance silevertinib into pivotal development[5]. - The company intends to seek FDA feedback on a potential registrational path for silevertinib in the first half of 2026[5]. Cash and Funding - The company ended Q3 2025 with approximately $135.5 million in cash, cash equivalents, and investments, up from $98.6 million as of December 31, 2024[5]. - The company expects to have sufficient funds to support operations into Q4 2027[6].